{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:48:53Z","timestamp":1791103733700,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,11,4]],"date-time":"2004-11-04T00:00:00Z","timestamp":1099526400000},"content-version":"vor","delay-in-days":2318,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1998,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The potential antiparkinsonian effects of the centrally acting, subtype\u2010selective neuronal nicotinic acetylcholine receptor agonist (S)\u2010(7\u2010)\u2010\u20105\u2010ethynyl\u20103\u2010(1\u2010methyl\u20102\u2010pyrrolidinyl)\u2010pyridine (SIB\u20101508Y) was assessed on motor symptoms and disability scale ratings in three monkeys previously made parkinsonian by chronic exposure to the dopaminergic neurotoxin 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP). Compared with levodopa (\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa), SIB\u20101508Y exerted only mild antiparkinsonian effects when administered alone. Emetic effects of this drug interfered with potential therapeutic effects at higher doses. However, when a low, ineffective dose of SIB\u20101508Y was combined with low, ineffective doses of\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa, a significant clinical effect was observed. These data suggest that subtype\u2010selective nicotinic acetylcholine receptor agonists may hold promise as antiparkinsonian agents, and when administered in combination with\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa may allow a reduction in the dose of\n                    <jats:sc>L<\/jats:sc>\n                    \u2010dopa needed to achieve a significant clinical effect.\n                  <\/jats:p>","DOI":"10.1002\/mds.870130405","type":"journal-article","created":{"date-parts":[[2005,5,28]],"date-time":"2005-05-28T20:46:41Z","timestamp":1117313201000},"page":"637-642","source":"Crossref","is-referenced-by-count":56,"title":["Effects of SIB\u20101508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys"],"prefix":"10.1002","volume":"13","author":[{"given":"Jay S.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pope\u2010Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Van Velson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Menzaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kenneth Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,11,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.11.1490"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.6.1041"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(88)90092-3"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(88)90094-8"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(89)90092-X"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)92967-N"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90040-B"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(87)90152-2"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(91)90075-H"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490300410"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.3416.1079"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244882"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(93)90150-W"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245195"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1987.tb01013.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)11471-8"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)91518-7"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0022-3565(24)36402-X","article-title":"Pharmacological characterization of SIB\u20101765F: a novel cholinergic ion channel agonist","volume":"280","author":"Sacaan AI","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0022-3565(24)36403-1","article-title":"Effects of a novel cholinergic ion channel agonist SIB\u20101765F on locomotor activity in rats","volume":"280","author":"Menzaghi F","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-3565(24)36404-3","article-title":"Interactions between a novel cholinergic ion channel agonist, SIB\u20101765F and l\u2010dopa in the reserpine model of Parkinson's disease in rats","volume":"280","author":"Menzaghi F","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm960328w"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1350379"},{"key":"e_1_2_1_24_2","first-page":"1110","article-title":"SIB\u20101765F, a novel nicotinic agonist: profile in models of extrapyramidal motor dysfunction","volume":"21","author":"Lloyd GK","year":"1995","journal-title":"Society for Neuroscience Abstracts"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(91)90080-8"},{"key":"e_1_2_1_26_2","first-page":"11","volume-title":"Noradrenergic Mechanisms in Parkinson's Disease","author":"Hornykiewicz O","year":"1994"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0022-3565(25)30363-0","article-title":"The neurochemistry of Parkinson's disease: effect of l\u2010dopa therapy","volume":"195","author":"Lloyd GK","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1993.tb05838.x"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90588-M"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870130405","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870130405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:23:30Z","timestamp":1760966610000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870130405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,7]]}},"alternative-id":["10.1002\/mds.870130405"],"URL":"https:\/\/doi.org\/10.1002\/mds.870130405","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,7]]}}}